Pictet Asset Management’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$92.6M Buy
2,393,515
+594,747
+33% +$20.8M 0.09% 243
2026
Q1
$68.8M Buy
1,798,768
+1,686,292
+1,499% +$62.3M 0.07% 264
2025
Q4
$4.23M Buy
112,476
+98,602
+711% +$2.77M ﹤0.01% 822
2025
Q3
$199K Sell
13,874
-8,577
-38% -$102K ﹤0.01% 1878
2025
Q2
$161K Buy
22,451
+8,577
+62% +$47.5K ﹤0.01% 1872
2025
Q1
$83.1K Hold
13,874
﹤0.01% 1956
2024
Q4
$108K Hold
13,874
﹤0.01% 1973
2024
Q3
$150K Buy
+13,874
New +$135K ﹤0.01% 1891

Other funds holding COGT

Pictet Asset Management's COGT Position: Q2 2026 in Review

Pictet Asset Management increased its Cogent Biosciences (COGT) stake by 33% in Q2 2026, buying an estimated $20.8M and bringing the position to 2,393,515 shares worth $92.6M. The position accounts for 0.09% of the portfolio, ranked #243.

Pictet Asset Management first reported a position in COGT in Q3 2024 and has held it in 8 quarters since. 47 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Pictet Asset Management held 2,393,515 shares of Cogent Biosciences worth $92.6M as of Q2 2026.
  • Pictet Asset Management bought 594,747 Cogent Biosciences shares in Q2 2026, an estimated $20.8M.
  • Cogent Biosciences made up 0.09% of Pictet Asset Management's portfolio in Q2 2026, its #243 holding.
  • Pictet Asset Management first reported a position in Cogent Biosciences in Q3 2024 and has held it in 8 quarters since.
  • 47 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.